Access cutting-edge waldenstrom's macroglobulinemia treatment through this clinical trial at a research site in Danville. Study-provided care at no cost to qualified participants.
Access waldenstrom's macroglobulinemia specialists in Danville at no cost
This study follows strict safety protocols and ethical guidelines
All study-related waldenstrom's macroglobulinemia treatment provided free
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this waldenstrom's macroglobulinemia clinical trial in Danville, IL
If you're searching for waldenstrom's macroglobulinemia treatment options in Danville, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Danville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced waldenstrom's macroglobulinemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.